Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.

Marcela S RialMaría L ScaliseEva C ArrúaMónica I EstevaClaudio Javier SalomonLaura E Fichera

Published in: PLoS neglected tropical diseases (2017)

Based on these findings, this research highlights the in-vitro/in-vivo efficacy of nanoformulated BNZ against T. cruzi acute infections in immunosuppressed and non-immunosuppressed mice and provides further evidence for the optimization of dosage regimens to treat Chagas disease.

Keyphrases

liver failure
respiratory failure
drug induced
aortic dissection
hepatitis b virus
type diabetes
metabolic syndrome
high fat diet induced
insulin resistance